Drug Trial Radar · NCT04958239
A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer
Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
151
Actual
Start
Oct 18, 2021
Primary completion
Apr 27, 2026
Study completion Feb 17, 2028
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Jul 12, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is open to adults with advanced cancer (solid tumors) and people with advanced head and neck cancer. The study has 2 parts. The purpose of Part 1 of this study is to find the highest dose of a medicine called BI 765179 that people with solid tumors can tolerate when taken alone or together with a medicine called ezabenlimab. The goal of Part 2 is to find out whether BI 765179 in combination with a medicine called pembrolizumab helps people with advanced head and neck cancer. In Part 1, each participant is put into 1 of 2 groups. Participants get BI 765179 alone or in combination with ezabenlimab as infusion into a vein every 3 weeks. In Part 2, participants are also divided into 2 groups. 1 group gets a low dose of BI 765179 in combination with pembrolizumab and the other group gets a high dose of BI 765179 in combination with pembrolizumab. Participants receive the study treatment as infusions into a vein. BI 765179, ezabenlimab, and pembrolizumab are antibodies that may help the immune system fight cancer. In this study, BI 765179 is given to people for the first time. Participants can stay in the study up to 2 years if they benefit from treatment and can tolerate it. The doctors regularly check the participants' health and note any health problems that could have been caused by the study treatment.
Conditions
- Neoplasms
Interventions
BI 765179Drug
BI 765179
EzabenlimabDrug
Ezabenlimab
PembrolizumabDrug
Pembrolizumab
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1a: Maximum Tolerated Dose (MTD)Time frame: Up to Day 21 (end of Cycle 1)
- Phase 1a: Occurrence of Dose Limiting Toxicities (DLTs) in the MTD evaluation periodTime frame: Up to Day 21 (end of Cycle 1)
- Phase 1b: Objective response (OR)Time frame: Up to 2 years.
Locations
48 sites in 15 countries. Site status is shown where the registry gives one.
University of Arizona
Tucson, Arizona
Beverly Hills Cancer Center
Beverly Hills, California
The University of North Carolina at Chapel Hill
Chapel Hill, North Carolina
Avera Cancer Institute
Sioux Falls, South Dakota
NEXT Oncology-San Antonio-65273
San Antonio, Texas
Border Cancer Hospital
Albury, New South Wales, Australia
Kinghorn Cancer Centre
Darlinghurst, New South Wales, Australia
Townsville Hospital
Douglas, Queensland, Australia
Austin Hospital
Heidelberg, Victoria, Australia
Cliniques Universitaires Saint-Luc
Brussels, Belgium
Universitair Ziekenhuis Antwerpen
Edegem, Belgium
AZ Groeninge
Kortrijk, Belgium
ICESP - Instituto do Cancer do Estado de Sao Paulo
São Paulo, Brazil
Hospital Sírio Libanês-São Paulo-68088
São Paulo, Brazil
Beneficência Portuguesa - Real e Benemérita Associação Portuguesa de Beneficência
São Paulo, Brazil
The First Affiliated Hospital Of Bengbu Medical College
Bengbu, China
Hunan Province Tumor Hospital
Changsha, China
Fujian Cancer Hospital
Fuzhou, China
Affiliated Cancer Hospital and Institute of Guangzhou Medical University
Guangzhou, China
Union Hospital Tongji Medical College Huazhong University of Science and Technology
Wuhan, China
Masaryk Memorial Cancer Institute
Brno, Czechia
HOP Saint-André
Bordeaux, France
CTR Georges-François Leclerc
Dijon, France
INS Cancérologie Ouest Saint-Herblain
Saint-Herblain, France
Universitätsklinikum Freiburg
Freiburg im Breisgau, Germany
Martin-Luther-Universität Halle-Wittenberg
Halle, Germany
Klinikum Stuttgart
Stuttgart, Germany
Shaare-Zedek Medical Center, Oncology Institute
Jerusalem, Israel
Sourasky Medical Center
Tel Aviv, Israel
Istituto Nazionale IRCCS Tumori Fondazione Pascale
Naples, Italy
Aichi Cancer Center Hospital
Aichi, Nagoya, Japan
National Cancer Center Hospital East
Chiba, Kashiwa, Japan
Kanagawa Cancer Center
Kanagawa, Yokohama, Japan
Kansai Medical University Hospital
Osaka, Hirakata, Japan
Osaka International Cancer Institute
Osaka, Osaka, Japan
Instituto Nacional de Cancerologia
México, Mexico
Centro Oncologico Internacional
Mexico City, Mexico
Hospital Universitario Dr Jose Eleuterio Gonzalez
Monterrey, Mexico
Fundación Santos y de la Garza Evia, I.B.P
Monterrey, Mexico
VU University Medical Center
Amsterdam, Netherlands
Showing 40 of 48 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.